| Objective: To explore the effect of trimodal prerehabilitation on clinical efficacy and quality of life in patients with non-small cell lung cancer (NSCLC) during the first-line chemotherapy. Methods: A total of 86 patients with NSCLC were selected from Oncology Center of Xuzhou Central Hospital from January 2019 to June 2021, and they were randomly divided into observation group (43 cases) and control group (43 cases). The observation group received first-line chemotherapy combined with trimodal prerehabilitation treatment, and the control group only received first-line chemotherapy. The clinical effect after treatment was compared between two groups, and quality of life was evaluated by FACT-L scale. Results: After two cycles of chemotherapy, the effective rate (CR+PR+SD) in the observation group was 81.4%, slightly higher than 76.7% of the control group, but there was no significant difference. The incidence of nausea and vomiting in the observation group was lower than that in the control group (P<0.05). Using FACT-L scale, the scores of PWB, EWB, FWB and LCS as well as the total score in the observation group were significantly higher than those before treatment (P<0.05), they were also higher than those in the control group after treatment (P<0.05). Conclusion: When trimodal prerehabilitation is combined with first-line chemotherapy to treat NSCLC patients, it reduces adverse reaction of nausea and vomiting without influencing efficacy. It can improve the scores of PWB, EWB, FWB and LCS, enhancing the overall quality of life effectively. |
